Search research articles
Contact Us
Filters
Showing results (171-180 of 347) with videos related to
Page
of 35
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
December 11, 2021
Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay
Shuxia Liu, Jianliang Yang, Sheng Yang, et al.
Cancer Immunology, Immunotherapy : CII
|
April 3, 2023
Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC
Shasha Wang, Guangyu Fan, Lin Li, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
January 28, 2015
[Efficacy analysis of different follow-up methods in detecting first recurrence of lymphoma]
Jianliang Yang, Yuankai Shi, Xiaohui He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2008
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma
Michael Wang, Liang Zhang, Xiaohong Han, et al.
Journal of Cancer
|
February 13, 2020
Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
Shiyu Jiang, Yan Qin, Peng Liu, et al.
Cancer Biology & Medicine
|
November 22, 2021
Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
Yan Qin, Haizhu Chen, Peng Liu, et al.
The Journal of Experimental Medicine
|
September 28, 2005
FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer
Tong Sun, Yifeng Zhou, Hua Li, et al.
Annals of Hematology
|
November 19, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified
Fei Qi, Mei Dong, Xiaohui He, et al.
Translational Oncology
|
December 16, 2014
Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population
Xiaohong Han, Zhishang Zhang, Di Wu, et al.
Oncotarget
|
April 15, 2017
Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type
Wumin Dai, Bo Jia, Jianliang Yang, et al.
Page
of 35
Search research articles
Search
Showing results (171-180 of 347) with videos related to
Sort By:
Page
of 35
Journal of Pharmaceutical and Biomedical Analysis
|
December 11, 2021
Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay
Shuxia Liu, Jianliang Yang, Sheng Yang, et al.
Cancer Immunology, Immunotherapy : CII
|
April 3, 2023
Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC
Shasha Wang, Guangyu Fan, Lin Li, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
January 28, 2015
[Efficacy analysis of different follow-up methods in detecting first recurrence of lymphoma]
Jianliang Yang, Yuankai Shi, Xiaohui He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2008
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma
Michael Wang, Liang Zhang, Xiaohong Han, et al.
Journal of Cancer
|
February 13, 2020
Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
Shiyu Jiang, Yan Qin, Peng Liu, et al.
Cancer Biology & Medicine
|
November 22, 2021
Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
Yan Qin, Haizhu Chen, Peng Liu, et al.
The Journal of Experimental Medicine
|
September 28, 2005
FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer
Tong Sun, Yifeng Zhou, Hua Li, et al.
Annals of Hematology
|
November 19, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified
Fei Qi, Mei Dong, Xiaohui He, et al.
Translational Oncology
|
December 16, 2014
Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population
Xiaohong Han, Zhishang Zhang, Di Wu, et al.
Oncotarget
|
April 15, 2017
Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type
Wumin Dai, Bo Jia, Jianliang Yang, et al.
Page
of 35